Objective CARAMBA is proposing to use the revolutionary CAR-T cell technology to tackle multiple myeloma, a rare and incurable hematologic malignancy. Myeloma is associated with a substantial socioeconomic burden and there is a strong demand by patients, their families and caregivers for a curative myeloma treatment. The CARAMBA investigators will conduct a phase I/II clinical trial of immunotherapy with patient-derived T cells that are engineered to express a synthetic chimeric antigen receptor (CAR) specific for the myeloma antigen SLAMF7. SLAMF7 is uniformly expressed on all myeloma cells in every patient, and SLAMF7 CAR-T cells will be equally effective in women and men. The efficacy and safety of SLAMF7 CAR-T cells has been validated by the coordinator in comprehensive pre-clinical testing which highlighted their unprecedented curative potential. SLAMF7 CAR-T cells have received an orphan designation for the indication multiple myeloma by the EC. The successful conduct, rapid and complete recruitment into the clinical trial is ensured by participation of 4 clinical myeloma centres of excellence in 4 EU member states, and the largest myeloma patient advocacy group in Europe, MPE. The SME partners in CARAMBA are prepared to develop the SLAMF7 CAR product all the way to market authorization. CAR-T cell therapy has been recognized as a ‘Breakthrough Therapy’ and clinical proof-of-concept obtained with CD19 CAR-T cells in leukemia and lymphoma. CARAMBA is building on novel and proprietary, cutting-edge CAR technologies including virus-free Sleeping Beauty CAR gene-transfer from DNA minicircles which substantially reduces the cost of CAR-T cell manufacturing, making it an economically viable and sustainable medicinal product. We are confident, that if funded, CARAMBA will accomplish its objective to establish the role of CAR-T cell therapy as a therapeutically effective, commercially attractive and socioeconomically desirable treatment in myeloma and other rare diseases. Fields of science medical and health sciencesmedical biotechnologygenetic engineeringgene therapymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesbasic medicineimmunologyimmunotherapymedical and health sciencesclinical medicineoncologyleukemiamedical and health sciencesmedical biotechnologycells technologies Keywords Multiple myeloma Hematologic malignancy Cancer immunotherapy Cellular therapy Chimeric antigen receptor CAR T-cell therapy Genetic engineering Sleeping Beauty SLAMF7 Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) SC1-PM-08-2017 - New therapies for rare diseases Call for proposal H2020-SC1-2016-2017 See other projects for this call Sub call H2020-SC1-2017-Two-Stage-RTD Funding Scheme RIA - Research and Innovation action Coordinator UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT Net EU contribution € 2 399 915,96 Address JOSEF-SCHNEIDER-STRASSE 2 97080 Wurzburg Germany See on map Region Bayern Unterfranken Würzburg, Kreisfreie Stadt Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 2 399 915,96 Participants (11) Sort alphabetically Sort by Net EU contribution Expand all Collapse all OSPEDALE SAN RAFFAELE SRL Italy Net EU contribution € 603 125,00 Address VIA OLGETTINA 60 20132 Milano See on map Region Nord-Ovest Lombardia Milano Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 748 125,00 Third-party Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure. UNIVERSITA VITA-SALUTE SAN RAFFAELE Italy Net EU contribution € 145 000,00 Address VIA OLGETTINA 58 20132 Milano See on map Region Nord-Ovest Lombardia Milano Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 145 000,00 UNIVERSIDAD DE NAVARRA Spain Net EU contribution € 512 375,00 Address CAMPUS UNIVERSITARIO EDIFICIO CENTRAL 31080 Pamplona See on map Region Noreste Comunidad Foral de Navarra Navarra Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 512 375,00 CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE France Net EU contribution € 250 272,50 Address AVENUE OSCAR LAMBRET 2 59037 Lille See on map Region Hauts-de-France Nord-Pas de Calais Nord Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 250 272,50 BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL Germany Net EU contribution € 342 875,00 Address PAUL-EHRLICH-STRASSE 51-59 63225 Langen See on map Region Hessen Darmstadt Offenbach, Landkreis Activity type Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 342 875,00 DRK-BLUTSPENDEDIENST BADEN-WURTTEMBERG-HESSEN GGMBH Germany Net EU contribution € 878 000,00 Address FRIEDRICH EBERT STRASSE 107 68167 Mannheim See on map Region Baden-Württemberg Karlsruhe Mannheim, Stadtkreis Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 878 000,00 MYELOMA PATIENTS EUROPE AISBL Belgium Net EU contribution € 115 625,00 Address AVENUE LOUISE 143 4 1050 BRUXELLES See on map Region Région de Bruxelles-Capitale/Brussels Hoofdstedelijk Gewest Région de Bruxelles-Capitale/ Brussels Hoofdstedelijk Gewest Arr. de Bruxelles-Capitale/Arr. Brussel-Hoofdstad Activity type Other Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 115 625,00 NBE-THERAPEUTICS AG Participation ended Switzerland Net EU contribution € 99 436,54 Address HOCHBERGERSTRASSE 60C TECHNOLOGIE PARK BASEL 4057 Basel See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Schweiz/Suisse/Svizzera Nordwestschweiz Basel-Stadt Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 99 436,54 T-CURX GMBH Germany Net EU contribution € 453 750,00 Address FRIEDRICH-BERGIUS-RING 15 97076 Wurzburg See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Bayern Unterfranken Würzburg, Kreisfreie Stadt Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 453 750,00 ARTTIC France Net EU contribution € 152 493,74 Address 39 RUE DES MATHURINS 75008 Paris See on map Region Ile-de-France Ile-de-France Paris Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 152 493,74 ARTTIC INNOVATION GMBH Germany Net EU contribution € 145 006,26 Address OSKAR-VON-MILLER-RING 29 80333 Munchen See on map Region Bayern Oberbayern München, Kreisfreie Stadt Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 145 006,26
